Sheng-Xing Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sheng-Xing Tang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Qian-Qiu Zhu
Department of Cardiology, Yijishan Hospital of Wannan Medical College, Wuhu, China
2 shared publications- Qing-Hua Zhong
Department of Cardiology, Longgang Central Hospital of Shenzhen, Shenzhen, China
2 shared publications Yan Sun
Department of Cardiology, Longgang Central Hospital of Shenzhen, Shenzhen, China
2 shared publicationsJia-Kang He
Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, China
1 shared publicationXiao Han
Institute of Cardio-Cerebrovascular Medicine, Central Hospital of Dalian University of Technology, Dalian, China
1 shared publication- Xiao Han
Institute of Cardio-Cerebrovascular Medicine, Central Hospital of Dalian University of Technology, Dalian, China
1 shared publication
Latest Publications
- 19 August 2025
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 103 (11-12) , 1405-1416
4-Hydroxychalcone alleviated Angiotensin II-induced atrial fibrillation via immunoproteasome-IKK-NF-κB signaling pathway modulation
Atrial Fibrillation (AF) is the most common type of cardiac arrhythmia and a significant contributor to stroke occurrence. Although 4-Hydroxychalcone (4HCH
- 19 August 2025
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 103 (11-12) , 1405-1416
4-Hydroxychalcone alleviated Angiotensin II-induced atrial fibrillation via immunoproteasome-IKK-NF-κB signaling pathway modulation
Atrial Fibrillation (AF) is the most common type of cardiac arrhythmia and a significant contributor to stroke occurrence. Although 4-Hydroxychalcone (4HCH
- Open Access
- 24 December 2024
- Published by Springer Nature in Hypertension Research
- Vol. 48 (3) , 1054-1067
4-Hydroxychalcone attenuates AngII-induced cardiac remodeling and dysfunction via regulating PI3K/AKT pathway
Cardiac remodeling encompasses structural alterations such as hypertrophy, fibrosis, and dilatation, alongside numerous cellular and molecular functional aberrations, constituting a pivotal process in the advancement of heart failure (HF). 4-Hydroxychalcone (4-HCH) is a class of naturally occurring compounds with variable phenolic structures, and has demonstrated the preventive efficacy in hyperaldosteronism, inflammation and renal injury. However, the role of 4-HCH in the regulation of cardiac remodeling remains uncertain. A cardiac remodeling model was established in male C57BL/6 J mice via subcutaneous Ang II (1000 or 300 ng/kg/min) for 2 weeks. Mice were treated with 4-HCH (20 or 40 mg/kg/day) or vehicle control. Systolic blood pressure (SBP) was measured using a tail-cuff method, and echocardiography assessed cardiac function. Histopathological staining evaluated cardiomyocyte hypertrophy, fibrosis, inflammation, and superoxide production. Network pharmacology analysis identified potential core targets and pathways mediating the effects of 4-HCH. Expression of inflammatory cytokines and proteins related to hypertrophy, fibrosis, inflammation, and oxidative stress was assessed by quantitative real-time PCR (qPCR) and Western blotting. Our results indicated that 4-HCH significantly ameliorated Ang II-induced hypertension, cardiomyocyte hypertrophy, fibroblast activation, fibrosis, inflammation, superoxide production, and cardiac function. Network pharmacology analysis identified the PI3K-AKT pathway as a crucial mechanism underlying the effects of 4-HCH, with experimental verification demonstrating that it inhibits cardiac remodeling by downregulating this pathway and its downstream effectors, including mTOR/ERK, TGF-β/Smad2/3, NF-κB, and NOX1 independent of its blood pressure-lowering effects. These results reveal for the first time that 4-HCH alleviates cardiac remodeling, emphasizing its potential as a therapeutic agent for HF.
- 24 December 2024
- Published by Springer Nature in Hypertension Research
- Vol. 48 (3) , 1054-1067
Open Access4-Hydroxychalcone attenuates AngII-induced cardiac remodeling and dysfunction via regulating PI3K/AKT pathway
Cardiac remodeling encompasses structural alterations such as hypertrophy, fibrosis, and dilatation, alongside numerous cellular and molecular functional aberrations, constituting a pivotal process in the advancement of heart failure (HF). 4-Hydroxychalcone (4-HCH) is a class of naturally occurring compounds with variable phenolic structures, and has demonstrated the preventive efficacy in hyperaldosteronism, inflammation and renal injury. However, the role of 4-HCH in the regulation of cardiac remodeling remains uncertain. A cardiac remodeling model was established in male C57BL/6 J mice via subcutaneous Ang II (1000 or 300 ng/kg/min) for 2 weeks. Mice were treated with 4-HCH (20 or 40 mg/kg/day) or vehicle control. Systolic blood pressure (SBP) was measured using a tail-cuff method, and echocardiography assessed cardiac function. Histopathological staining evaluated cardiomyocyte hypertrophy, fibrosis, inflammation, and superoxide production. Network pharmacology analysis identified potential core targets and pathways mediating the effects of 4-HCH. Expression of inflammatory cytokines and proteins related to hypertrophy, fibrosis, inflammation, and oxidative stress was assessed by quantitative real-time PCR (qPCR) and Western blotting. Our results indicated that 4-HCH significantly ameliorated Ang II-induced hypertension, cardiomyocyte hypertrophy, fibroblast activation, fibrosis, inflammation, superoxide production, and cardiac function. Network pharmacology analysis identified the PI3K-AKT pathway as a crucial mechanism underlying the effects of 4-HCH, with experimental verification demonstrating that it inhibits cardiac remodeling by downregulating this pathway and its downstream effectors, including mTOR/ERK, TGF-β/Smad2/3, NF-κB, and NOX1 independent of its blood pressure-lowering effects. These results reveal for the first time that 4-HCH alleviates cardiac remodeling, emphasizing its potential as a therapeutic agent for HF.